1. Raz R. Fosfomycin: an old–new antibiotic. Clin Microbiol Infect 2012; 18: 4–7.
2. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011; 15(11): e732-9.
3. Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis 2010; 29(2): 127-42.
4. Hazırolan G. Fosfomycin: Flashback. Klimik Derg 2020; 33(3): 213-22.
5. Baylan O. Fosfomisin: Dünü, Bugünü ve Geleceği. Mikrobiyol Bul 2010; 44: 311-321.
6. Garau J. Other antimicrobials of interest in the era of extendedspectrum s-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 2008; 14(Suppl 1): 198-202.
7. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Clin Microbiol Rev 2016; 29: 321–347.
8. Krause R, Patruta S, Daxböck F, Fladerer P, Wenisch C. The effect of fosfomycin on neutrophil function. J Anbmicrob Chemother 2001; 47: 141–146.
9. Mohd Sazlly Lim S, Heffernan AJ, Roberts JA, Sime FB. Semimechanistic Pharmacokinetic/Pharmacodynamic Modeling of Fosfomycin and Sulbactam Combination against Carbapenem-Re-
sistant Acinetobacter baumannii. Antimicrob Agents Chemother 65:10.1128/aac.02472-20.
10. Zhu W, Wang Y, Cao W, Cao S, Zhang J. In vitro evaluation of antimicrobial combinations against imipenem-resistant Acinetobacter baumannii of different MICs. J Infect Public Health 12018;
1: 856–86.
11. Wei W, Yang H, Liu Y, Ye Y, Li J. In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase. J Chemother 2016;
28: 159–163.
12. Adaleti R, Nakipoğlu Y, Arıcı N, et al. Evaluation of In vitro Efficacy of Meropenem/Colistin and Meropenem/Fosfomycin Combinations on Multidrug Resistant Gram-Negative Bacilli.
Mikrobiyol Bul 2023; 57(3): 365-377.
13. Simsek M. Sensitivity of extended spectrum of β-lactamase producing Escherichia coli and Klebsiella species to Fosfomycin. J Pak Med Assoc 2020; 70(7): 1187-1192.
14. Pujol M, Miró JM, Shaw E, et al. Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-Resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Cli-
nical Trial. Clin. Infect. Dis 2021; 72: 1517–1525.
15. van den Bijllaardt W, Schijffelen MJ, Bosboom RW, et al. Susceptibility of ESBL Escherichia coli and Klebsiella pneumoniae to fosfomycin in the Netherlands and comparison of several testing
methods including Etest, MIC test strip, Vitek2, Phoenix and disc diffusion. J Antimicrob Chemother 2018; 73(9): 2380-2387.
16. Croughs PD, Konijnendijk-de Regt M, Yusuf E. Fosfomycin susceptibility testing using commercial agar dilution test. Microbiol Spectr 2022; 10(2): e0250421.
17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; thirty-second ed. CLSI supplement M100-S32. Wayne, PA: Clinical and Laboratory
Standards Institute; 2022.
18. European Committee on Antimicrobial Susceptibility Testing. 2024. Breakpoint tables for interpretation of MICs and zone diameters; version 14.0. http://www.eucast.org.
19. Mattioni Marchetti V, Hrabak J, Bitar I. Fosfomycin resistance mechanisms in Enterobacterales: an increasing threat. Front Cell Infect Microbiol 2023; 13: 1178547.
20. Kim DH, Lees WJ, Kempsell KE, et al. Characterization of a Cys115 to asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that
confersresistance to inactivation by the antibiotic fosfomycin. Biochemistry 1996; 35 (15): 4923-4928.
21. Takahata S, Ida T, Hiraishi T, et al. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents 2010; 35 (4): 333–337.
22. Patel SS, Balfour JA, Bryson HM. Fosfomycin tromtheamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficiacy as a single dose oral teatment for acute
uncomplicated lower urinary tract infections. Drugs 1997; 53(4): 637-56).
23. Rodríguez-Gascón A, Canut-Blasco A Rev Esp Quimioter 2019; 32: 19-24.
24. Reza SM et al. Therapeubcs and Clinical Risk Management 2019; 15: 525–530.
25. Pharmacotherapy 2014;34:845 AAC 2015;59:7170)).
26. Zhanel GG, Zhanel MA Karlowsky JA. Intravenous fosfomycin: An assessment of its potential for use in the treatment of systemic infections in Canada. Can J Infect Dis Med Microbiol 2018;
8912039.
27. Konwar M, Gogtay NJ, Ravi R, Thatte UM, Bose D. Evaluation of efficacy and safety of fosfomycin versus nitrofurantoin for the treatment of uncomplicated lower urinary tract infection (UTI)
in women – A systematic review and meta-analysis. J Chemother 2022; 34(3): 139-148.
28. Shafrir A, Oster Y, Shauly-Aharonov M, Strahilevitz J. Real-Life Comparison of Fosfomycin to Nitrofurantoin for the Treatment of Uncomplicated Lower Urinary Tract Infection in Women.
Biomedicines 2023; 11(4): 1019.
29. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative
Infections. Clin Infect Dis 2023: ciad428.
30. Huttner A, Kowalczyk A, Turjeman A, et al. Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A
Randomized Clinical Trial. JAMA 2018; 319(17): 1781-1789.
31. Ten Doesschate T, Kuiper S, van Nieuwkoop C, et al. Fosfomycin Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized,
Placebo-Controlled, Double-Blind, Multicenter Trial. Clin Infect Dis 2022; 75(2): 221-229.
32. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum betalactamase- producing Escherichia coli-related lower urinary
tract infections. Int J Antimicrob Agents 2007; 29(1): 62–65.
33. Cai T, Novelli A, Tascini C, Stefani S. Rediscovering the value of fosfomycin trometamol in the era of antimicrobial resistance: A systematic review and expert opinion. Int J Antimicrob Agents
2023; 62(6): 106983.
34. European Medicines Agency. Fosfomycin-containing medicinal products. https://www.ema.europa.eu/en/medicines/human/referrals/fosfomycin-containing-medicinal-products (accessed
on 28 February 2024)
35. Real-life experience with IV fosfomycin in Canada: Results from the Canadian LEadership on Antimicrobial Real-life usage (CLEAR) registry)
36. Stengel D, Gorzer E, Schintler M, et al., Second-line treatment of limb-threatening mikroorganiz diabetic foot infections with intravenous fosfomycin. J Chemother 2005; 17(5): 527–53.
37. Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review
38. Wittmann D. Chemotherapeutic principles of difficult-to-treat infections in surgery: II. Bone and joint infections. Infection 1980; 8(6): 330–333.
39. Del Río A, Gasch O, Moreno A, et al. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococ-
cus aureus: a multicenter clinical trial. Clin Infect Dis 2014; 59(8): 1105-12.
40. Delgado V, Ajmone Marsan N, de Waha S;et al. 2023 ESC Guidelines for the Management of Endocarditis: Developed by the Task Force on the Management of Endocarditis of the European
Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM). Eur Heart J 2023; 44:
3948–4042.
41. Kollef MH, Ricard JD, Roux D, et al. A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator- Associated Pneumonia:
IASIS Trial. Chest 2017;151(6): 1239-1246.
42. Tobudic S, Matzneller P, Stoiser B, et al. Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis. Antimicrob Agents
Chemother 2012; 56(7): 3992-3995.
43. Reeves DS. Treatment of bacteriuria in pregnancy with single dose fosfomycin trometamol: a review. Infection 1992; 20(Suppl 4): 313-316.
44. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011; 15(11): e732-9.
45. UpToDate: Fosfomycin Drug Information. 2024. http:// www.uptodate.com/contents/fosfomycin-drug-information (Accessed February 2024).
46. Mayama T, Yokota M, Shimatani I, Ohyagi H. Analysis of oral fosfomycin calcium (Fosmicin) side-effects after marketing. Int J Clin Pharmacol Ther Toxicol 1993; 31: 77–82.
47. Matusik E, Demanet J, Alves I, et al. Fosfomycin-induced agranulocytosis: a case report and review of the literature. BMC Infect Dis 2023; 23(1): 685